Generation of Induced Pluripotent Stem Cells from Human Peripheral T Cells Using Sendai Virus in Feeder-free Conditions

Kishino, Yoshikazu; Seki, Tomohisa; Yuasa, Shinsuke; Fujita, Jun; Fukuda, Keiichi

doi:10.3791/53225

Cited by 10 publications

(6 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using the modified technique described recently by the Fukuda and Wu laboratories in Japan and the US, respectively 43,44 , our team has reproduced hiPSCs utilizing PB cells 45 . We have evolved this technique to use a non-integrating Sendai virus to reprogram CD71 + PB iPSCs from healthy donors and then differentiate them into functional cardiomyocytes.…”

Section: Methodsmentioning

confidence: 99%

Evaluation of Multiple Biological Therapies for Ischemic Cardiac Disease

et al. 2016

View full text Add to dashboard Cite

The development of cell-and gene-based strategies for regenerative medicine offers a therapeutic option for the repair and potential regeneration of damaged cardiac tissue post-myocardial infarction (MI). Human umbilical cord subepithelial cell-derived stem cells (hUC-SECs), human bone marrow-derived mesenchymal stem cells (hBM-MSCs), and human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), all derived from human tissue, have been shown to have in vitro and in vivo therapeutic potential. Additionally, S100a1, VEGF165, and stromal-derived factor-1a (SDF-1a) genes all have the potential to improve cardiac function and/or effect adverse remodeling. In this study, we compared the therapeutic potential of hBM-MSCs, hUCSECs, and hiPSC-CMs along with plasmid-based genes to evaluate the in vivo potential of intramyocardially injected biologics to enhance cardiac function in a mouse MI model. Human cells derived from various tissue types were expanded under hypoxic conditions and injected intramyocardially into mice that had undergone left anterior descending (LAD) artery ligation. Similarly, plasmids were also injected into three groups of mice after LAD ligation. Seven experimental groups were studied in total: (1) control (saline), (2) hBM-MSCs, (3) hiPSC-CMs, (4) hUC-SECs, (5) S100a1 plasmid, (6) VEGF165 plasmid, and (7) SDF-1a plasmid. We evaluated echocardiography, hemodynamic catheterization measurements, and histology at 4 and 12 weeks postbiologic injection. Significant improvement was observed in cardiac function and contractility in hiPSC-CM and S100a1 groups and a significant reduction in left ventricle scar within the hUC-SEC group and a slight improvement in the SDF-1a and VEGF165 groups compared to the control group. These results demonstrate the potential for new biologic therapies to reduce scar burden and improve contractile function.

show abstract

Section: Methodsmentioning

confidence: 99%

Evaluation of Multiple Biological Therapies for Ischemic Cardiac Disease

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In addition, Sendai virus vector is capable to infect a vast host range and are non-pathogenic to humans. Among viral vectors, it has been considered a quintessential tool for cell reprogramming and stem cell research [ 35 ].…”

Section: Methods Of Generation Of Ipscsmentioning

confidence: 99%

Induced pluripotent stem cell: A headway in reprogramming with promising approach in regenerative biology

Rawat

Singh

2017

Vet World

View full text Add to dashboard Cite

Since the embryonic stem cells have knocked the doorsteps, they have proved themselves in the field of science, research, and medicines, but the hovered restrictions confine their application in human welfare. Alternate approaches used to reprogram the cells to the pluripotent state were not up to par, but the innovation of induced pluripotent stem cells (iPSCs) paved a new hope for the researchers. Soon after the discovery, iPSCs technology is undergoing renaissance day by day, i.e., from the use of genetic material to recombinant proteins and now only chemicals are employed to convert somatic cells to iPSCs. Thus, this technique is moving straightforward and productive at an astonishing pace. Here, we provide a brief introduction to iPSCs, the mechanism and methods for their generation, their prevailing and prospective applications and the future opportunities that can be expected from them.

show abstract

“…TiPSC was generated following the previous protocol (Kishino et al, 2015). Briefly, the cultured PBMCs were collected by pipetting and centrifuged at 200 g for 5 min at RT.…”

Section: Generation Of Tipscmentioning

confidence: 99%

“…TiPSC was generated from human peripheral blood using a protocol reported previously (Kishino et al, 2014(Kishino et al, , 2015Matsumoto et al, 2016). Activated human mononuclear cells were isolated from 10 ml of human peripheral blood.…”

Section: Derivation and Generation Of Tipscsmentioning

confidence: 99%

Transplantation of reprogrammed peripheral blood cells differentiates into retinal ganglion cells in the mouse eye with NMDA‐induced injury

Zhou

Rui

Peng

et al. 2021

Journal Cellular Physiology

View full text Add to dashboard Cite

The generation of patient-specific induced pluripotent stem cells (iPSCs) holds significant implications for replacement therapy in treating optic neuropathies such as glaucoma. Stem-cell-based therapy targeted at replacing and replenishing retinal ganglion cells is progressing at a fast pace. However, clinical application necessitates an efficient and robust approach for cell manufacturing. Here, we examine whether the embryo body derived from human peripheral blood-derived iPSC can localize into the host retina and differentiate into retinal ganglion cells after transplantation into a glaucoma injury model. Human peripheral blood T cells were isolated and reprogrammed into an induced pluripotent stem cell (TiPSC) line using Sendai virus transduction carrying transcription factors Sox2, Klf4, c-Myc, and Oct4. TiPSCs were differentiated into RGC using neural basal culture. For in vivo studies, embryo bodies derived from TiPSCs (TiPSC-EB) were injected into the vitreous cavity of N-Methyl-D-aspartic acid (NMDA)-treated mice 2 weeks before sacrifice and retinal dissection. Induced pluripotent stem cells generated from human peripheral blood T cells display stem cell morphology and pluripotency markers. Furthermore, RGC-like cells differentiated from TiPSC exhibit extending axons and RGC marker TUJ1.When transplanted intravitreally into NMDA-treated mice, embryo bodies derived from TiPSC survived, migrated, and incorporated into the retina's GCL layer. In addition, TiPSC-EB transplants were able to differentiate into TUJ1 positive RGC-like cells. Retinal ganglion cells can be differentiated using human peripheral blood cells derived iPSC. Transplantation of embryo body derived from TiPSCs into a glaucoma mouse model could incorporate into host GCL and differentiate into RGC-like cells.

show abstract

Generation of Induced Pluripotent Stem Cells from Human Peripheral T Cells Using Sendai Virus in Feeder-free Conditions

Cited by 10 publications

References 29 publications

Evaluation of Multiple Biological Therapies for Ischemic Cardiac Disease

Evaluation of Multiple Biological Therapies for Ischemic Cardiac Disease

Induced pluripotent stem cell: A headway in reprogramming with promising approach in regenerative biology

Transplantation of reprogrammed peripheral blood cells differentiates into retinal ganglion cells in the mouse eye with NMDA‐induced injury

Contact Info

Product

Resources

About